Hong Kong Studies Show Tyzeka Superior To Epivir, Hepsera In Fighting HBV (China)
This article was originally published in PharmAsia News
A pair of university studies in Hong Kong conclude Idenix's Tyzeka (telbivudine) for treating chronic hepatitis B is better than commonly prescribed treatments for suppressing the hepatitis B virus. The studies compared GlaxoSmithKline's Epivir (lamivudine) and Gilead's Hepsera (adefovir dipivoxil) with Tyzeka and said 60 percent of patients on the Idenix drug ended up with non-detectable HBV in their blood. The studies in the New England Journal of Medicine and the Annals of Internal Medicine found 40 percent of patients on the other two drugs achieved that outcome after a year. Tyzeka is priced between the prices of the other two. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.